Estrella Immunopharma Reports 100% Complete Response in Second Dose Cohort of EB103 Trial for Advanced B-Cell Non-Hodgkin’s Lymphoma

According to Towards Healthcare Study, Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical innovator developing CD19 and CD22-targeted ARTEMIS® T-cell therapies for autoimmune and oncological diseases, has announced outstanding results from the second dose cohort of its Phase 1 STARLIGHT-1 clinical trial evaluating EB103 for the treatment of Advanced B-cell Non-Hodgkin’s Lymphoma (NHL). The company reported a 100% complete response (CR) rate within one month among all patients treated in this second dose cohort — a remarkable milestone in the treatment of relapsed or refractory (R/R) B-cell NHL, especially among high-risk patients who were ineligible for commercial CD19 therapies, including one participant with Central Nervous System (CNS) lymphoma. Equally notable, no serious treatment-related adverse events (SAEs) were observed during the trial, underscoring EB103’s favorable safety profile in a population that traditionally faces limited therapeutic options.

About the Second Dose Cohort

The second dose cohort enrolled patients with refractory or relapsed B-cell NHL who had previously failed multiple lines of therapy. Following treatment, a Data and Safety Monitoring Board (DSMB) — an independent expert committee overseeing patient safety and study progress — will review cumulative safety and efficacy data to recommend the Recommended Phase 2 Dose (RP2D) for the next phase of the trial. The Phase 1/2 STARLIGHT-1 study is a multi-center, open-label, dose-escalation and dose-expansion trial designed to assess both the safety and preliminary efficacy of EB103, an autologous T-cell therapy, in adult patients aged 18 and older with R/R B-cell NHL. Phase 1 focuses on dose escalation and safety evaluation, while Phase 2 aims to explore the therapy’s clinical benefit at the RP2D.

Leadership Remarks

Dr. Cheng Liu, Chief Executive Officer of Estrella Immunopharma, commented on the milestone:

“The completion of the second dose cohort with a 100% CR rate marks a major achievement in our EB103 clinical program. We’re encouraged by the therapy’s excellent safety profile, even in a high-risk patient population — including those with CNS involvement. These findings highlight EB103’s potential as a safe and effective treatment option for patients with limited alternatives. We’re now preparing to advance to the dose extension phase of the STARLIGHT-1 trial.”

Next Steps

Estrella Immunopharma plans to initiate the extension phase of STARLIGHT-1 following DSMB evaluation, moving closer to establishing EB103 as a next-generation T-cell therapy for hard-to-treat hematologic malignancies. If subsequent phases confirm these early results, EB103 could represent a significant breakthrough in the management of advanced B-cell NHL, potentially redefining therapeutic standards for patients who have exhausted current treatment avenues. Read Complete News at: https://www.towardshealthcare.com/news/estrella-eb103-phase-1-trial-results Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: https://www.towardshealthcare.com/access-dashboard Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting You can place an order or ask any questions, please feel free to contact us at [email protected] Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 APAC Region: +91 9356 9282 04 Visit Our Website: https://www.towardshealthcare.com Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest